IL82841A - Ligands and in vitro methods for augmenting b-cell proliferation - Google Patents

Ligands and in vitro methods for augmenting b-cell proliferation

Info

Publication number
IL82841A
IL82841A IL82841A IL8284187A IL82841A IL 82841 A IL82841 A IL 82841A IL 82841 A IL82841 A IL 82841A IL 8284187 A IL8284187 A IL 8284187A IL 82841 A IL82841 A IL 82841A
Authority
IL
Israel
Prior art keywords
augmenting
ligands
cell proliferation
vitro methods
vitro
Prior art date
Application number
IL82841A
Other languages
English (en)
Other versions
IL82841A0 (en
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of IL82841A0 publication Critical patent/IL82841A0/xx
Priority to IL99427A priority Critical patent/IL99427A0/xx
Publication of IL82841A publication Critical patent/IL82841A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0635B lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL82841A 1986-06-13 1987-06-10 Ligands and in vitro methods for augmenting b-cell proliferation IL82841A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL99427A IL99427A0 (en) 1986-06-13 1991-09-06 Pure 50 kilodalton b cell surface antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13

Publications (2)

Publication Number Publication Date
IL82841A0 IL82841A0 (en) 1987-12-20
IL82841A true IL82841A (en) 1992-11-15

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
IL82841A IL82841A (en) 1986-06-13 1987-06-10 Ligands and in vitro methods for augmenting b-cell proliferation

Country Status (22)

Country Link
JP (1) JPH0762040B2 (xx)
KR (1) KR910004100B1 (xx)
AT (1) AT398437B (xx)
AU (1) AU617087B2 (xx)
BE (1) BE1000587A4 (xx)
CA (1) CA1338781C (xx)
CH (1) CH676600A5 (xx)
CY (1) CY1681A (xx)
DE (1) DE3719398C2 (xx)
DK (1) DK173940B1 (xx)
FR (1) FR2607136B1 (xx)
GB (1) GB2191494B (xx)
GR (1) GR870930B (xx)
HK (1) HK10293A (xx)
IE (1) IE60486B1 (xx)
IL (1) IL82841A (xx)
IT (1) IT1208649B (xx)
LU (1) LU86919A1 (xx)
NL (1) NL195022C (xx)
PT (1) PT85073B (xx)
SE (1) SE504675C2 (xx)
SG (1) SG118992G (xx)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CO4600681A1 (es) 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (en) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monoclonal antibody specific for monocytes and blast cells
FR2547731A1 (fr) * 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
IL82841A0 (en) 1987-12-20
SE8702463D0 (sv) 1987-06-12
AU617087B2 (en) 1991-11-21
GB8713650D0 (en) 1987-07-15
NL8701371A (nl) 1988-01-04
SG118992G (en) 1993-01-29
GR870930B (en) 1987-12-16
IE871563L (en) 1987-12-13
IE60486B1 (en) 1994-07-27
GB2191494A (en) 1987-12-16
CH676600A5 (xx) 1991-02-15
DE3719398A1 (de) 1988-01-28
PT85073B (pt) 1990-07-31
GB2191494B (en) 1990-08-22
FR2607136A1 (fr) 1988-05-27
SE8702463L (sv) 1987-12-14
KR910004100B1 (ko) 1991-06-22
JPS6480299A (en) 1989-03-27
SE504675C2 (sv) 1997-04-07
DK173940B1 (da) 2002-03-04
ATA151387A (de) 1994-04-15
HK10293A (en) 1993-02-19
JPH0762040B2 (ja) 1995-07-05
DK302287A (da) 1987-12-14
NL195022C (nl) 2003-06-18
CY1681A (en) 1993-10-10
DK302287D0 (da) 1987-06-12
AT398437B (de) 1994-12-27
PT85073A (en) 1987-07-01
AU7421487A (en) 1987-12-17
IT1208649B (it) 1989-07-10
IT8720899A0 (it) 1987-06-12
BE1000587A4 (fr) 1989-02-14
LU86919A1 (fr) 1989-03-08
KR880000582A (ko) 1988-03-28
FR2607136B1 (fr) 1989-09-15
DE3719398C2 (de) 1996-03-28
CA1338781C (en) 1996-12-10

Similar Documents

Publication Publication Date Title
NZ221811A (en) Process and intermediate for preparing sucrose-6-acylates
YU198087A (en) Process for obtaining nor-statine and nor-cyclostatine
EP0328027A3 (en) Novel soluble polyimidesiloxanes and methods for their preparation and use
ZA892508B (en) Picnic trailer apparatus
ZW4683A1 (en) Homogeneous human immune interferon and process therefor
HU886790D0 (en) Neutrophilous activating factor and process for its preparation
GB2262637B (en) Method and circuitry for digital system multiplication
IL88321A0 (en) Sialocylglycerolipids and method for preparing same
IL82841A (en) Ligands and in vitro methods for augmenting b-cell proliferation
GB2188259B (en) Article supporting fixture and method
GB2190331B (en) Improvements in ring binders
EP0360301A3 (en) Coating method in coating line and coating apparatus therefor
ZA876598B (en) Bromofluoroethylhypofluorite and process for its preparation
GB2187159B (en) Improvements relating to apparatus for supporting and manipulating objects
DE3660253D1 (en) Method for preparing copper-diamine complexes and diamines
GB8921252D0 (en) Nodular silver powder and process for preparing silver powder
GB2236806B (en) Turbocharger apparatus
CS131388A1 (en) 2-nitrophenyl-4-/n-carboxyphenyl-sulphonamid and process for preparing thereof
IL82372A0 (en) 2-vinylpenams and process
CA55765S (en) Combined table and seats
KR900007967Y1 (en) Multi-purposal cam apparatus in cdp
CS510787A1 (en) 3-/2-alkylthio-6-benzolylaminomethyl/-6-brom-2-benzothialinones and process for preparing them
GB2196560B (en) Improvements in sharpening apparatus
CS566686A1 (en) Process for preparing d-glycero-d-galactoheptose and d-glycero-d-taloheptose
GB8724604D0 (en) Variable contour back support

Legal Events

Date Code Title Description
EXP Patent expired